找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Chemokines; Chemokines and Their Nuska Tschammer Book 2015 Springer International Publishing Switzerland 2015 Allosteric Modulation.CXCR3 T

[復制鏈接]
樓主: 從未沮喪
11#
發(fā)表于 2025-3-23 10:06:07 | 只看該作者
Selective and Dual Targeting of CCR2 and CCR5 Receptors: A Current Overview,ory processes fueled the use of CCR5 antagonists for the treatment of rheumatoid arthritis. Unfortunately, the use of maraviroc for the treatment of rheumatoid arthritis failed due to its inefficacy. Some of the ligands, e.g., TAK-779 and TAK-652, were also found to be dual antagonists of CCR2 and C
12#
發(fā)表于 2025-3-23 14:58:38 | 只看該作者
Book 2015roughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known
13#
發(fā)表于 2025-3-23 20:16:06 | 只看該作者
Werner Dickmeis,Rolf Joachim Nesselpact of structures on rational molecular design initiatives. As an inherently challenging family of GPCRs, chemokine receptors may only reveal their secrets when tackled by the efficient symbiosis of computational approaches with experimental structure determination.
14#
發(fā)表于 2025-3-24 01:26:00 | 只看該作者
https://doi.org/10.1007/978-3-322-87917-2ory processes fueled the use of CCR5 antagonists for the treatment of rheumatoid arthritis. Unfortunately, the use of maraviroc for the treatment of rheumatoid arthritis failed due to its inefficacy. Some of the ligands, e.g., TAK-779 and TAK-652, were also found to be dual antagonists of CCR2 and C
15#
發(fā)表于 2025-3-24 06:20:34 | 只看該作者
16#
發(fā)表于 2025-3-24 06:57:59 | 只看該作者
17#
發(fā)表于 2025-3-24 11:15:28 | 只看該作者
Chemokine Receptors in Allergy, Inflammation, and Infectious Disease,coupled receptors, which represent one of the most druggable classes of proteins. In this review we will examine the role of chemokines in autoimmunity and inflammation by concentrating on the part they play in the pathophysiology of several diseases including asthma, multiple sclerosis, and rheumat
18#
發(fā)表于 2025-3-24 16:27:16 | 只看該作者
19#
發(fā)表于 2025-3-24 22:16:20 | 只看該作者
20#
發(fā)表于 2025-3-25 00:54:44 | 只看該作者
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-16 18:22
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
长海县| 丰都县| 汾西县| 阳泉市| 高阳县| 陆川县| 朝阳区| 南召县| 瓮安县| 嘉义市| 芷江| 股票| 阿克| 大荔县| 梓潼县| 临桂县| 长垣县| 罗田县| 祁门县| 金门县| 镶黄旗| 忻城县| 阿拉善左旗| 唐河县| 留坝县| 永修县| 漾濞| 江陵县| 白河县| 北辰区| 泸州市| 茂名市| 万安县| 连江县| 大关县| 安宁市| 拉萨市| 历史| 峨山| 金昌市| 渝北区|